Coagulation Profile for Cryoprecipitate Produced From 24-Hour Stored Whole Blood

The possible advantages of cryoprecipitate prepared from fresh frozen plasma from blood stored for 24 hours

BACKGROUND

To compare the coagulation-factor profile of cryoprecipitate produced from fresh frozen plasma from whole blood (WB) stored for 24 hours at room temperature (24CP) with that of standard cryoprecipitate (CP).

METHODS

We collected 80 units of WB from healthy volunteers, of which 20 units were of each blood group. Each unit of blood was divided into 2 parts. One part was used for preparation and quality-control evaluation of CP within 8 hours of collection; the other part was stored at room temperature for 24 hours and then subjected to CP preparation. Coagulation studies were carried out on each batch of CP after production. Fibrinogen, Factor VIII (FVII), and von Willibrand factor (vWF) were measured, and the blood groups were determined. We used the Student's t-test to perform comparisons and considered results to be significant at P < .005.

RESULTS

Overall, all 3 clotting factors were increased in 24CP compared with CP, with a statistically significant increase in the level of FVIII. Blood group AB had significantly increased levels of fibrinogen and vWF in 24CP compared with CP.

CONCLUSION

Our study showed that 24CP has equal or greater levels of coagulation factors compared with CP. His indicates that our alternate approach for preparation of CP may enable more efficient use of blood collected in satellite blood collection centers and during blood drives.

Preparation of cryoprecipitate from riboflavin and UV light-treated plasma

BACKGROUND AND OBJECTIVES

The Mirasol® pathogen reduction technology system for plasma is based on a riboflavin and UV light treatment process resulting in pathogen inactivation due to irreversible, photochemically induced damage of nucleic acids. This study was undertaken to evaluate the possibility of making pathogen reduced cryoprecipitate from riboflavin and UV light- treated plasma that meets the quality requirements specified by UK and European guidelines for untreated cryoprecipitate.

MATERIALS AND METHODS

Cryoprecipitate was made from riboflavin and UV light-treated plasma. Plasma units were thawed over a 20 h period at 4°C, and variable centrifugation settings (from 654 g for 2 min to 5316 g for 6 min) were applied to identify the optimal centrifugation condition. Plasma proteins in cryoprecipitate units were characterized on a STA Compact, Diagnostica STAGO and Siemens BCS analyzer.

RESULTS

Neither the centrifugation speed or time appeared to have an effect on the quality of the final cryoprecipitate product; however the initial solubilization of the cryoprecipitate product was found to be easier at the lower centrifugation setting (654 g for 2 min). Cryoprecipitate units prepared from Mirasol-treated plasma demonstrated protein levels that were less than levels in untreated products, but were on average 93 IU/unit, 262 mg/unit and 250 IU/unit for FVIII, fibrinogen and von Willebrand ristocetin cofactor activity, respectively.

CONCLUSION

Cryoprecipitate products prepared from Mirasol-treated plasma using a centrifugation method contain levels of fibrinogen, FVIII and von Willebrand ristocetin cofactor activity, that meet both the European and UK guidelines for untreated cryoprecipitate. Flexibility in centrifugation conditions should allow blood banks to use their established centrifugation settings to make cryoprecipitate from Mirasol-treated plasma.